Skip to main content

Generics

  • Teva leader to exit company in May, former Bristol executive to step in

    JERUSALEM — Teva Pharmaceutical Industries announced that Shlomo Yanai, president and CEO, will retire from his post in May.

    Yanai, who has served in this capacity for five years, has helped Teva expand from a mainly generics business to a more diversified pharmaceutical company, with expected 2012 revenue of approximately $22 billion, and an expanded footprint in the European, Asian and Latin America markets.

  • Study analyzes potential benefits of MTM integration

    The role of the pharmacist has evolved considerably over the past decade, and few things exemplify that evolution more than pharmacists taking an active role in patients’ medication therapies and consulting with them one-on-one.


  • Baxter, Momenta partner on biosimilar development

    NEW YORK — Baxter and Momenta have agreed to partner to develop and market biosimilar  drugs to treat cancer, autoimmune disorders and other chronic conditions.

  • Actavis, QRxPharma partner to sell MoxDuo IR

    MORRISTOWN, N.J. — Drug maker Actavis is partnering with QRxPharma to sell what the former called a novel pain drug in the United States.

    The company said Wednesday that the two had signed a letter of intent to commercialize MoxDuo IR (morphine and oxycodone), which they plan to launch in third quarter 2012.

  • Amneal launches felbamate oral suspension

    BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched its generic version of a drug designed to treat seizures in adults and children with epilepsy.

    The generic drug maker said it received approval from the Food and Drug Administration on Dec. 16 for felbamate oral suspension in the 600-mg/5-mL strength. The Amneal generic is available in two sizes, 8 fl. oz./240 mL and 16 fl. oz./473 mL. It is a generic version of Meda Pharmaceuticals' antiepileptic Felbatol.

  • Ranbaxy settles cGMP issues with U.S. government

    GURGAON, India — Ranbaxy Labs said Wednesday that it had resolved long-standing issues concerning two of its manufacturing plants in India with the U.S. government.

  • Watson, Amgen partner to develop biosimilars

    PARSIPPANY, N.J. — Generic drug maker Watson and biotech manufacturer Amgen will work together to develop biosimilar antibodies for treating cancer, the two companies said.

  • Upsher-Smith launches women's health portal

    MAPLE GROVE, Minn. — Upsher-Smith has launched an online portal for advanced-practice clinicians interested in women's health, the company said.

    Clinicians Corner provides nurse practitioners, physician assistants, nurses and midwives with resources and educational materials.

X
This ad will auto-close in 10 seconds